Cytosorbents (CTSO) Operating Income Growth (1y) (2012 - 2026)
Cytosorbents (CTSO) Operating Income Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | -20.56% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 11.83% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 30.43% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 19.54% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 20.97% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 90.95% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 74.18% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | -18.12% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Cytosorbents | 22.58 Mn | 17.78 Mn | 6.13 Mn | 21.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.71% |
| Dec 31, 2025 | -29.16% |
| Sep 30, 2025 | 40.75% |
| Jun 30, 2025 | -1.26% |
| Mar 31, 2025 | 16.50% |
| Dec 31, 2024 | 63.91% |
| Sep 30, 2024 | 34.29% |
| Jun 30, 2024 | 45.57% |
| Mar 31, 2024 | 41.00% |
| Dec 31, 2023 | -48.01% |
| Sep 30, 2023 | 18.49% |
| Jun 30, 2023 | 21.51% |
| Mar 31, 2023 | -1.29% |
| Dec 31, 2022 | 33.52% |
| Sep 30, 2022 | -66.80% |
| Jun 30, 2022 | -69.70% |
| Mar 31, 2022 | -173.16% |
| Dec 31, 2021 | -262.98% |
| Sep 30, 2021 | -175.87% |
| Jun 30, 2021 | -49.34% |